Roussy–Lévy syndrome

Jump to navigation Jump to search

WikiDoc Resources for Roussy–Lévy syndrome

Articles

Most recent articles on Roussy–Lévy syndrome

Most cited articles on Roussy–Lévy syndrome

Review articles on Roussy–Lévy syndrome

Articles on Roussy–Lévy syndrome in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Roussy–Lévy syndrome

Images of Roussy–Lévy syndrome

Photos of Roussy–Lévy syndrome

Podcasts & MP3s on Roussy–Lévy syndrome

Videos on Roussy–Lévy syndrome

Evidence Based Medicine

Cochrane Collaboration on Roussy–Lévy syndrome

Bandolier on Roussy–Lévy syndrome

TRIP on Roussy–Lévy syndrome

Clinical Trials

Ongoing Trials on Roussy–Lévy syndrome at Clinical Trials.gov

Trial results on Roussy–Lévy syndrome

Clinical Trials on Roussy–Lévy syndrome at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Roussy–Lévy syndrome

NICE Guidance on Roussy–Lévy syndrome

NHS PRODIGY Guidance

FDA on Roussy–Lévy syndrome

CDC on Roussy–Lévy syndrome

Books

Books on Roussy–Lévy syndrome

News

Roussy–Lévy syndrome in the news

Be alerted to news on Roussy–Lévy syndrome

News trends on Roussy–Lévy syndrome

Commentary

Blogs on Roussy–Lévy syndrome

Definitions

Definitions of Roussy–Lévy syndrome

Patient Resources / Community

Patient resources on Roussy–Lévy syndrome

Discussion groups on Roussy–Lévy syndrome

Patient Handouts on Roussy–Lévy syndrome

Directions to Hospitals Treating Roussy–Lévy syndrome

Risk calculators and risk factors for Roussy–Lévy syndrome

Healthcare Provider Resources

Symptoms of Roussy–Lévy syndrome

Causes & Risk Factors for Roussy–Lévy syndrome

Diagnostic studies for Roussy–Lévy syndrome

Treatment of Roussy–Lévy syndrome

Continuing Medical Education (CME)

CME Programs on Roussy–Lévy syndrome

International

Roussy–Lévy syndrome en Espanol

Roussy–Lévy syndrome en Francais

Business

Roussy–Lévy syndrome in the Marketplace

Patents on Roussy–Lévy syndrome

Experimental / Informatics

List of terms related to Roussy–Lévy syndrome

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Roussy–Lévy syndrome
Classification and external resources
ICD-10 G60.0
ICD-9 334.3
OMIM 180800

Overview

Roussy–Lévy syndrome, also known as Roussy–Lévy hereditary areflexic dystasia, is a rare genetic disorder of humans that results in progressive muscle wasting. It is caused by mutations in the genes that code for proteins necessary for the functioning of the myelin sheath of the neurons, affecting the conductance of nerve signals and resulting in loss of muscles' ability to move.

The condition affects people from infants through adults and is inherited in an autosomal dominant manner. Currently, no cure is known for the disorder.

Signs and symptoms

Symptoms of the Roussy–Lévy syndrome mainly stem from nerve damage and the resulting progressive muscle atrophy. Neurological damage may result in absent tendon reflexes (areflexia), some distal sensory loss and decreased excitability of muscles to galvanic and faradic stimulation. Progressive muscle wasting results in weakness of distal limb muscles (especially the peronei), gait ataxia, pes cavus, postural tremors and static tremor of the upper limbs, kyphoscoliosis, and foot deformity.[1]

These symptoms frequently translate into delayed onset of ability to walk, loss of coordination and balance, foot drop, and foot-bone deformities. They are usually first observed during infancy or early childhood, and slowly progress until about age 30, at which point progression may stop in some individuals, or symptoms may continue to slowly progress.[2]

Causes

The Roussy–Lévy syndrome has been associated with two genetic mutations: a duplication of the PMP22 gene that carries the instructions for producing the peripheral myelin protein 22, a critical component of the myelin sheath; and a missense mutation in the MPZ gene which codes for myelin protein zero, a major structural protein of peripheral myelin.[3][4][1][5]

As PMP22 mutations are also associated with Charcot–Marie–Tooth disease type 1A and MPZ mutations are associated with Charcot–Marie–Tooth disease type 1B, it remains the subject of discussion whether the Roussy–Lévy syndrome is a separate entity or a specific phenotype of either disorder.[4]

Pathophysiology

In common with other types of Charcot–Marie–Tooth disease, neurological examination reveals decreased nerve conduction velocity and histologic features of a hypertrophic demyelinating neuropathy.[6] Electromyography shows signs of mild neurogenic damage[5][7] while nerve biopsy shows onion bulb formations; the appearance of these formations is what primarily led Gustave Roussy and Gabrielle Lévy, the scientists who first described the disorder, to classify it as a variant of Charcot–Marie–Tooth disease.[4]

To create a working nerve, neurons, Schwann cells, and fibroblasts must work together. Molecular signals are exchanged between Schwann cells and neurons to regulate survival and differentiation of a nerve. However, these signals are disrupted in patients with the Roussy–Lévy syndrome.

Diagnosis

While the clinical picture may point towards the diagnosis of the Roussy–Lévy syndrome, the condition can only be confirmed with absolute certainty by carrying out genetic testing in order to identify the underlying mutations.

Treatment and management

There is no pharmacological treatment for Roussy–Lévy syndrome.

Treatment options focus on palliative care and corrective therapy. Patients tend to benefit greatly from physical therapy (especially water therapy as it does not place excessive pressure on the muscles), while moderate activity is often recommended to maintain movement, flexibility, muscle strength and endurance.[3]

Patients with foot deformities may benefit from corrective surgery, which, however, is usually a last resort. Most such surgeries include straightening and pinning the toes, lowering the arch, and sometimes, fusing the ankle joint to provide stability. Recovering from these surgeries is oftentimes long and difficult. Proper foot care including custom-made shoes and leg braces may minimize discomfort and increase function.[4][8]

While no medicines are reported to treat the disorder, patients are advised to avoid certain medications as they may aggravate the symptoms.

Prognosis

The Roussy–Lévy syndrome is not a fatal disease and life expectancy is normal. However, due to progressive muscle wasting patients may need supportive orthopaedic equipment or wheelchair assistance.[4]

History

In 1926, scientists Gustave Roussy and Gabrielle Lévy reported 7 cases within a same family of a dominantly inherited disorder over 4 generations.[4] They noticed that prominent features of this disorder were an unsteady gait during early childhood and areflexia, or the absence of reflexes, which eventually lead to clumsiness and muscle weakness. During a nerve biopsy of a few of the original patients, the demyelinating lesions found led the scientists to believe that the Roussy–Lévy syndrome was a variant of demyelinating Charcot–Marie–Tooth disease (CMT-1).[4]

See also

References

  1. 1.0 1.1 Template:Cite doi
  2. Template:Cite doi
  3. 3.0 3.1 Template:Cite doi
  4. 4.0 4.1 4.2 4.3 4.4 4.5 4.6 Template:Cite doi
  5. 5.0 5.1 Template:Cite doi
  6. Template:Cite doi
  7. PMID 10451742 (PMID 10451742)
    Citation will be completed automatically in a few minutes. Jump the queue or expand by hand
  8. Template:Cite doi